Doctronic secures major funding for AI-powered telemedicine
Doctronic secures major funding for AI-powered telemedicine
In a move that could redefine modern medicine, New York-based startup Doctronic has secured $40 million in Series B funding.
Founded in 2023, the company aims to tackle the U.S. healthcare access crisis by using an AI-native platform.
Unlike basic symptom checkers, Doctronic utilizes a unique multi-agent system where specialized AI agents simulate clinical grand rounds to formulate diagnoses, which are then validated by human doctors.
Operating in all 50 U.S. states, the company has seen massive adoption, with over 300,000 unique visitors weekly.
Recently, Doctronic hit a regulatory milestone by launching a pilot program in Utah, allowing AI to handle routine prescription refills.
Despite facing some scrutiny regarding safety vulnerabilities—which the company maintains do not impact their regulated pilot—Doctronic remains at the forefront of the shift toward AI-autonomous care.
By bridging the gap between "Dr.
Google" and traditional primary care, Doctronic is proving that AI can take legal responsibility for health outcomes, paving the way for a more efficient, accessible future.
